Zach works on both public and private investments and serves as a Board Director for Adagio Medical, Exo Imaging, LENZ Therapeutics, Nkarta Therapeutics, and Sydnexis. Prior to BEV, Kyle was a Principal at In-Q-Tel, the strategic investment arm of the CIA and US Intelligence Community, where he invested in early stage manufacturing, materials, energy, computing, and defense companies. He is also an active member of the Big Brothers of Massachusetts Bay program. Jaimie's primary responsibilities are to coordinate calendars, events, and company meetings for RA Venture Partners and EIRs. Early in his career, Mr. Grau worked with multi-national pharma companies including Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product launch. Prior to joining RAVen, Maryann was Director of Business Operations and HR at Q32 Bio where she wore many hats helping to establish the companys business infrastructure including IT, contract management, facilities, administrative support, Human Resources, recruiting, internal communications and was a strong driver of company culture. Largest investment: 7.9 million shares of Vor Biopharma worth $142 million at the time of its IPO . Robert has led multiple DARPA, IARPA, and NIH advanced technology development programs. As Head of Vaccines, he is leading the RA vaccine team to support our evidence-based investment strategy. More recently, Scott founded MissionGBM, a global community and resource focused on advancing brain cancer therapeutics development and care delivery. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. Emorys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. Prior to RA Capital, Tyler worked as a freelance graphic designer. Henrys primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Most recently, Brian served as Analyst, Biotech/Pharma/Specialty Pharma at Tamarack Capital Management. We owe a debt to the people who have mentored us, and we in turn have a responsibility to turn our hard won lessons into a solid foundation for our industry's emerging innovators and leaders.. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. Pieter holds a BA from Trinity College and a JD from Yale Law School. Prior to her stint coaching, she received her BS in Psychology with a Minor in History from Union College in NY. Ana is a Senior Research Assistant, Venture Analytics at RA Capital Management. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. Harvey holds an MS in Finance from Bentley University McCallum Graduate School of Business and a BS in Corporate Finance and Accounting from Bentley University. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. Kathryn has a BS in Exercise and Health Science from the University of Massachusetts Boston. He holds a Bachelors degree in Electronics and Communications from Anna University, and a Masters degree in Computer Science from Northeastern University. PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst Matt has a BA in Biology with minors in Mathematics and Physics from Ithaca College, a Master of Science in Bioinformatics from Northeastern University, and a PhD in Molecular Biology with a specialization in quantitative biology from Brandeis University. He holds Microsoft 365 and Microsoft certifications as Messaging Administrator Associate, Teams Administrator Associate, Teamwork Administrator Associate, and Azure Administrator Associate. Natalie holds a BA in Psychology from William Paterson University and a MA in Psychology from Seton Hall University. Peter has a BS in Biology with minors in both Chemistry and Spanish for the Medical Professions from the University of North Carolina at Chapel Hill. Nate conducts due diligence on biotechnology companies at RA Capital and serves as a Board Director for The Covid Apollo Project and Nucleix. Gabes primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Amber is Special Projects Operations Manager/Chief of Staff at RA Capital Management. Erins primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts. While at Acceleron he successfully launched the company's first blockbuster asset - REBLOZYL - and brought in the company's lead drug - Sotatercept - prior to Acceleron's eventual sale to Merck in 2021. Most recently, he was Chief Technology Officer at Vor Bio where he built the technical operations team responsible for process development, analytical development, supply chain and manufacturing support of a CRISPR gene-edited HSPC product and oversaw the companys CAR-T efforts. Prior to RA, she served as Researcher and Collaborator at New Care, a startup focused on improving access to early childcare for lower income families. Prior to moving to BMS, he spent five years at Hoffmann La-Roche as a research scientist. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP, where he was responsible for accounting and valuation for the credit fund business, as well as the management company (US and Europe) and associated functions. Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. He is a respected biotech leader with over twenty years of biopharma experience across global organizations. Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics, earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. BioSpace's List Of The Top 5 Biggest VC Vampires In Biotech He is the co-inventor of first-in-class HCV NS5A inhibitors, which led to the approval of DaklinzaTM, the first marketed drug in its class. In addition, Michael served on the firm's Luxembourg Board of Directors where he was responsible for accounting and financial reporting. Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors.
Remove Work Or School Account Windows 10 Registry,
Suzuki Cappuccino Dimensions,
Mcarthur Golf Club Membership Fees,
Mhgu Early G Rank Weapons,
Mimecast External Admin,
Articles P